PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
+34.19%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$710M
AUM Growth
+$710M
(+42%)
Cap. Flow
+$143M
Cap. Flow
% of AUM
20.2%
Top 10 Holdings %
Top 10 Hldgs %
64.6%
Holding
32
New
9
Increased
14
Reduced
4
Closed
5
Top Buys
| 1 |
Biogen
BIIB
|
$41.3M |
| 2 |
Akero Therapeutics
AKRO
|
$28.4M |
| 3 |
Axsome Therapeutics
AXSM
|
$23.2M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$21.7M |
| 5 |
Incyte
INCY
|
$14.5M |
Top Sells
| 1 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
$44.1M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$18.4M |
| 3 |
Arvinas
ARVN
|
$10.4M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
$7.01M |
| 5 |
United Therapeutics
UTHR
|
$4.71M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GBT
1
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $80.1M | 10.68% | 1,175,879 -269,687 | -19% | -$18.4M |
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $59.4M | 7.92% | 850,385 +190,417 | +29% | +$13.3M |
|
|
3
Incyte
INCY
$16.5B
| $51.5M | 6.87% | 773,082 +217,039 | +39% | +$14.5M |
|
4
Ascendis Pharma
ASND
$11.8B
| $51.4M | 6.85% | 497,347 +65,177 | +15% | +$6.73M |
|
5
Legend Biotech
LEGN
$6.41B
| $43.9M | 5.86% | 1,076,591 +97,995 | +10% | +$4M |
|
|
6
Biogen
BIIB
$19.4B
| $41.3M | 5.5% | +154,605 | New | +$41.3M |
|
7
Immunocore
IMCR
$1.62B
| $36.3M | 4.84% | 773,079 +105,662 | +16% | +$4.96M |
|
8
Viridian Therapeutics
VRDN
$1.5B
| $33.6M | 4.47% | 1,636,211 +329,642 | +25% | +$6.76M |
|
9
argenx
ARGX
$43.6B
| $31.9M | 4.25% | 90,297 +1,481 | +2% | +$523K |
|
|
10
United Therapeutics
UTHR
$13.8B
| $29.4M | 3.92% | 140,561 -22,505 | -14% | -$4.71M |
|
|
11
Akero Therapeutics
AKRO
$3.74B
| $28.4M | 3.78% | +833,265 | New | +$28.4M |
|
|
BCYC
12
Bicycle Therapeutics
BCYC
$511M
| $27M | 3.59% | 1,158,686 +110,170 | +11% | +$2.56M |
|
13
Syndax Pharmaceuticals
SNDX
$1.41B
| $26.1M | 3.48% | 1,085,142 +208,986 | +24% | +$5.02M |
|
|
14
Axsome Therapeutics
AXSM
$6.05B
| $23.2M | 3.09% | +520,080 | New | +$23.2M |
|
|
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $21.7M | 2.9% | +351,405 | New | +$21.7M |
|
|
ALPN
16
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $15.9M | 2.13% | 2,214,722 +1,387,943 | +168% | +$9.99M |
|
17
Prothena Corp
PRTA
$441M
| $14.3M | 1.91% | +235,826 | New | +$14.3M |
|
|
18
Arvinas
ARVN
$568M
| $12.6M | 1.68% | 283,777 -233,629 | -45% | -$10.4M |
|
19
Esperion Therapeutics
ESPR
$448M
| $11.5M | 1.54% | 1,719,831 +311,781 | +22% | +$2.09M |
|
20
Merus
MRUS
$4.98B
| $11.3M | 1.51% | 564,214 +111,970 | +25% | +$2.24M |
|
|
GTHX
21
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $11M | 1.47% | +884,574 | New | +$11M |
|
22
Crinetics Pharmaceuticals
CRNX
$2.92B
| $10.2M | 1.36% | +519,256 | New | +$10.2M |
|
|
OYST
23
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $9.26M | 1.24% | 1,648,316 +314,986 | +24% | +$1.77M |
|
24
TG Therapeutics
TGTX
$4.65B
| $8.91M | 1.19% | 1,505,479 -459,230 | -23% | -$2.72M |
|
|
PSTX
25
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $7.31M | 0.97% | +2,070,108 | New | +$7.31M |
|